Sagimet Biosciences Inc. Class A SGMT
NASDAQ · United States · Health Technology
$9.88+0.55 (+5.89%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Healthcare stocks declined Wednesday afternoon, with the NYSE Healthcare Index easing 0.3% and the S
Sagimet Biosciences Inc Series A (NASDAQ:SGMT) shares rose more than 12% in pre-market trading on Wednesday following the release of 52-week results from license partner Ascletis’ Phase 3 open-label extension trial evaluating denifanstat in patients with moderate to severe acne. The trial reported a 57% treatment success rate after 52 weeks of denifanstat treatment, alongside a 72% reduction in total lesions and a 77% reduction in inflammatory lesions.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Sagimet’s Denifanstat produced a 57% treatment-success rate after up to 52 weeks.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.